17 research outputs found
OBTAINING AND STUDYING THE OPTICAL PROPERTIES OF FILMS BASED ON CERIUM OXIDE NANOPARTICLES
Composites films based on cerium dioxide nanoparticles were obtained. Xanthan gum was used as a matrix. The properties of the films were evaluated using optical microscopy and optical spectrophotometry
EFFECT OF CERIUM OXIDE NANOPARTICLES DOPING WITH RARE EARTH ELEMENTS ON CATALYTIC ACTIVITY
The effect of cerium oxide nanoparticles doping with erbium and samarium ions on the redox properties was studied. Rare earth doped СеО2 nanoparticles exhibit higher catalase enzyme-like activity. Among doped samples, the erbium-doped СеО2 nanoparticles demon-strated the highest catalytic activity
Неоперабельный гепатоцеллюлярный рак — перспективы лекарственной терапии ленватинибом
There is a number of unresolved issues regarding the systemic therapy administration for hepatocellular carcinoma (HCC). Their solution is facilitated by accumulating real‑world study results. Lenvatinib therapy is a recognized drug with a good efficacy and safety profile for the treatment of HCC. Subanalyses of the REFLECT study showed that the absence of stratification by baseline AFP and baseline liver function, as well as the lack of options for subsequent drug therapy after lenvatinib, also affects the outcomes. Once these factors are taken into account, the hypothesis of superiority of lenvatinib to sorafenib and other drugs can be tested. Real‑world clinical studies have demonstrated positive results of lenvatinib therapy in patients with Child‑Pugh class B liver function, provided recommendations on the sequence of systemic therapy after lenvatinib and on the use of lenvatinib in patients with BCLC stage B, along with considering the possibility of lenvatinib monotherapy and the prospects for its use in patients with nHCC. Further real‑world studies of lenvatinib for HCC in the Russian population are required.В подходах к назначению лекарственной терапии гепатоцеллюлярного рака (ГЦР) есть ряд еще нерешенных вопросов. Их решению способствует накопление результатов исследований в реальной клинической практике. Методом медикаментозной терапии ГЦР с хорошим профилем эффективности и безопасности признана терапия ленватинибом. В субанализах исследования REFLECT показано, что отсутствие стратификации по исходному уровню альфа-фетопротеина и оценке исходной функции печени, а также дефицит опций последующей после назначения ленватиниба медикаментозной терапии оказывают влияние на результаты. Учет этих факторов даст возможность проверить гипотезу превосходства терапии ленватинибом в сравнении с сорафенибом и другими препаратами. В исследованиях реальной клинической практики продемонстрированы положительные результаты применения ленватиниба у пациентов с нарушением функции печени класса B по шкале Чайлд-Пью, даны рекомендации по последовательности системной терапии после ленватиниба, применению ленватиниба у пациентов стадии BCLC B, а также рассмотрены возможности монотерапии ленватинибом и перспективы его применения у пациентов с нГЦК. Необходимы дальнейшие исследования ленватиниба при ГЦР в реальной клинической практике на российской популяции
Regulation of immune cell function and differentiation by the NKG2D receptor
NKG2D is one of the most intensively studied immune receptors of the past decade. Its unique binding and signaling properties, expression pattern, and functions have been attracting much interest within the field due to its potent antiviral and anti-tumor properties. As an activating receptor, NKG2D is expressed on cells of the innate and adaptive immune system. It recognizes stress-induced MHC class I-like ligands and acts as a molecular sensor for cells jeopardized by viral infections or DNA damage. Although the activating functions of NKG2D have been well documented, recent analysis of NKG2D-deficient mice suggests that this receptor may have a regulatory role during NK cell development. In this review, we will revisit known aspects of NKG2D functions and present new insights in the proposed influence of this molecule on hematopoietic differentiation
Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI) : Study protocol for a multicentre, observational trial
More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369
СHEALTH EDUCATION AND ADHERENCE FORMATION IN SOCIALLY VULNERABLE GROUPS OF TUBERCULOSIS PATIENTS
The paper considers the incidence of tuberculosis in a pediatric population and mentally ill patients and describes the key problems of disease management in these patients. It gives data on patients’ awareness of their disease and factors forming their treatment adherence
Results of the study of morbidity and disability in children in Russia, North Caucasus Federal district and the Stavropol region for the years 2008-2012
The article presents the results of a study of morbidity and disability in children. It is noted that the primary morbidity of children under the age of 14 years in the Russian Federation and the North Caucasus Federal District has increased. In the Stavropol region is marked reduction of primary disease in general, but the recorded growth of primary morbidity of obesity (+12,96%), the same trends observed in the North Caucasus Federal District (+26,83%). Among the subjects of the district the maximum growth of primary disease occurred in the republics of Dagestan, Karachay-Cherkessia and Stavropol territory (+64,36%, +157,02%, +35,86% respectively). Despite the implemented projects in the health pediatricians decreased: in Russia by 1,9%, and North Caucasus Federal District Stavropol region - by 15,4%. The authors note the need for infrastructure rehabilitation and restorative treatment of children